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MRproADM (p  ! 0.0001). There was a significant negative 
correlation between fast walk and MMRC (R = –0.70; p  ! 
0.001) and fast walk was only independently predictive of 
MRproANP but not MRproADM once MMRC was excluded 
from the list of covariates (p = 0.023 and p = 0.057, respec-
tively).  Conclusions: Daily walking activity independently 
predicts levels of circulating MRproANP and MRproADM in 
stable COPD patients, two prognostic biomarkers of cardiac 
distress associated with long-term survival upon exacerba-
tion of COPD. Employing activity monitors in the stable state 
might simplify risk stratification in daily living. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The prevalence and incidence of Chronic Obstructive 
Pulmonary Disease (COPD) is rapidly increasing and ev-
idence suggests it will be the third leading cause of death 
worldwide within the next decade  [1–3] . Exacerbations of 
COPD are the most common cause of emergency respira-
tory admissions to hospitals and are a major financial bur-
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 Abstract 
 Background: The prevalence of cardiovascular mortality is 
high in Chronic Obstructive Pulmonary Disease (COPD) and 
the identification of clinical parameters to improve risk strat-
ification is of great interest.  Objectives: This study aims to 
assess the predictive strength of daily walking activity on ex-
pression of cardiac biomarkers in patients with COPD.  Meth-
ods: One hundred and five patients with COPD (66.1  8 8.7 
years of age) were prospectively analyzed. Daily walking ac-
tivity was measured by means of accelerometry. Stepwise 
multivariate regression analyses were employed with either 
midregional proatrial natriuretic peptide (MRproANP) or 
plasma proadrenomedullin (MRproADM) as dependent vari-
ables, and age, age-adjusted Charlson score, Modified Med-
ical Research Council Dyspnea Scale (MMRC), Saint Georges 
Respiratory Questionnaire total score and either total walk, 
steps per day or fast walk as covariates.  Results: Indepen-
dent predictors of MRproANP included age (p = 0.015) and 
either total walk or steps per day (both p  ! 0.0001). Total walk 
or steps per day were the only independent predictors of 
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den to health services  [4] . In addition, COPD is associated 
with high cardiovascular comorbidity and mortality and 
the prevalence for cardiovascular-related death remains 
particularly high in patients suffering acute  exacerbations 
of COPD  [5, 6] . Therefore, systemic biomarkers of inflam-
mation and/or cardiac stress have grown in significance 
regarding their ability to predict clinical prognosis in sta-
ble COPD and in the setting of severe acute exacerbations 
requiring hospital admission  [7–10] . Among these are 
midregional proatrial natriuretic peptide (MRproANP) 
and plasma proadrenomedullin (MRproADM). Both are 
markers of cardiac distress and have been shown to be in-
dependently predictive of 2-year long-term survival in pa-
tients with severe acute exacerbation of COPD  [11, 12] .
 Daily physical activity is another important predictor 
of mortality in this patient population  [10, 13, 14] . The 
degree of physical impairment significantly correlates 
with disease severity and markedly impacts the patient’s 
quality of life  [15–17] . The usefulness of accelerometers 
to measure daily activity levels is well documented in pa-
tients with COPD  [18–22] . They provide an objective 
measure of daily activity and are found to be more accu-
rate than questionnaires which tend to be subject to bias 
and typically overestimate the total amount of physical 
activity  [23] . Recent studies have demonstrated acceler-
ometer-based physical activity to be the strongest predic-
tor of all-cause mortality in patients with COPD  [10, 14] . 
Moreover, physical inactivity was shown to be an inde-
pendent predictor of hospital admission due to severe 
 exacerbation and was positively associated with higher 
numbers of exacerbations per year further increasing the 
risk for mortality  [14, 24] .
 Evidence suggests that physical activity attenuates and 
inactivity augments the occurrence of exacerbations of 
COPD due to underlying hemodynamic changes and va-
soconstriction of the pulmonary vasculature  [25–28] . 
Hence, the purpose of this study is to evaluate the asso-
ciation between accelerometer-based physical activity 
and prognostic biomarkers in stable COPD patients in 
order to establish whether ambulatory activity monitor-
ing can simplify risk stratification in daily living.
 Methods 
 Setting and Study Population 
 This prospective cohort study evaluates patients with COPD 
recruited in the ‘Predicting Effects and Risk Factors in Exacerba-
tions of Chronic Obstructive Pulmonary Disease’ (PROMISE) 
study  [29] . In brief, one of the primary endpoints of the study was 
to explore predictors that might identify recurrence and poor out-
come during and outside exacerbations. One hundred and five 
patients in the stable condition were consecutively included in 
this sub-study analysis at the Clinic of Pulmonary Medicine of the 
University Hospital Basel, Switzerland, between November 2008 
and March 2010.
 To be eligible for the study, patients had to be diagnosed with 
COPD on the basis of clinical history such as smoking status or 
physical examination, and to meet post-bronchodilator spiro-
metric criteria for COPD stage II–IV according to the GOLD 
guidelines at inclusion. Spirometry was performed by trained 
lung function technicians according to American Thoracic 
Guidelines  [30] . Once included, assessments included detailed 
medical history, current medication, duration of disease, comor-
bidities, physical examination, quality of life (Saint Georges 
 Respiratory Questionnaire; SGRQ)  [31] , Modified Medical 
 Research Council Dyspnea Scale (MMRC), spirometry, 8-day 
accelerometry and blood tests to assess MRproANP and 
MRproADM. Patients enrolled in the PROMISE study had an 
initial baseline examination followed by a total of four scheduled 
visits every 6 months. For this subgroup analysis, assessment of 
daily activity levels and prognostic biomarkers was carried out 
during a scheduled visit when patients were in a stable condition 
outside exacerbations. The study was carried out according to 
the principles of the Declaration of Helsinki and approved by our 
local ethics committee (Ethic Commission Beider Basel EKBB 
295/07). Written informed consent was obtained from all pa-
tients.
 Measurements of MRproADM and MRproANP 
 All three biomarkers were assessed in EDTA plasma from all 
patients using a sandwich immunoassay and documented on pa-
per case report forms. Automated immunoassays are based on 
sandwich chemiluminescene assays. The following assays were 
used according to the instructions of the manufacturer: BRAHMS 
MRproANP KRYPTOR (ThermoFisher Scientific, BRAHMS 
GmbH, Hennigsdorf, Germany) and BRAHMS MRproADM 
KRYPTOR (ThermoFisher Scientific). Detailed description of 
biomarker detection procedures can be read elsewhere  [32, 33] . 
The lower detection limit of the MRproANP assay was 4.3 pmol/l, 
and its functional sensitivity was 11 pmol/l with an interassay 
 coefficient of variation  ! 20%. The lower detection limit for the 
MRproADM assay was 0.08 pmol/l and its functional sensitivity 
was 0.12 pmol/l  [11, 12] .
 Accelerometer Activity Monitoring 
 Patients were handed the accelerometer (Aipermon  GmbH, 
Munich, Germany) during a scheduled visit and instructed to 
wear it continuously during waking hours whilst doing their nor-
mal daily routine. The device was attached to the patient’s belt and 
positioned above the left hip. Patients were encouraged to wear 
the device continuously during normal waking hours for 8 con-
secutive days. The accelerometer was to be attached upon rising 
in the morning and only to be taken off for showering, bathing 
and sleeping. The first and last days when patients received or re-
turned the device were incomplete and thus only 6 consecutive 
days (24 h) were included in the statistical analysis. All device set-
tings were preprogrammed for each patient to keep patient han-
dling of the accelerometer to a minimum. Patients did not receive 
any feedback from the device display regarding daily walking 
time, intensity or steps taken. Upon return, data were copied onto 
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a PC and their content was viewed via ActiCoach MPAT2Viewer, 
(Aipermon). Wearing time included minutes per day spent pas-
sively (i.e. sitting), actively (i.e. movement, but not walking), 
walking (0–5 km/h or 0–80 m/min), fast walking ( 1 5 km/h or 
81–115 m/min) and steps per day. Data was analyzed according to 
total walking time (min/day), walking intensity (fast walk  1 5 
km/h) and steps per day. Total walk was computed from adding 
the parameters walk + fast walk together. The device used was a 
three-dimensional accelerometer measuring movement continu-
ously in three axes (x, y, z). Data output is provided in 60-second 
intervals for each consecutive day (24 h) with the exact time and 
date for each epoch. Activity modes and accelerometer detection 
accuracy were extensively validated and detailed results are re-
ported elsewhere  [34, 35] . In summary, the device was able to ac-
curately detect steps to 99% at walking speeds ranging as low as 
20 m/min onwards. The device was originally designed for use in 
a large multi-center study investigating the feasibility of remote 
telemedical patient monitoring  [36–38] .
 Data Analysis 
 Statistical analysis was done using SPSS software (version 19.0, 
SPSS Inc., Chicago, Ill., USA). Data were descriptively analyzed 
reporting mean  8 standard deviation (SD) for quantitative mea-
surements and percentages for frequencies. Data for quantitative 
biomarker values were described as median interquartile range 
(IQR). Statistical comparisons of measurements across different 
GOLD stage categories were done using one-way ANOVA. Post 
hoc group differences were tested by unpaired Student’s t test and 
statistical significance was set at p  ^  0.05. Bivariate correlations 
were investigated using Pearson’s correlation coefficient (R). Cor-
relations were two tailed and statistically significant at the level of 
p  ^  0.01. Multivariate linear regression analyses were performed 
to assess the influence of age, age-adjusted Charlson score, MMRC 
Dyspnea Scale, SRGO total score and either total walking time, 
steps per day or fast walking, respectively, on circulating levels of 
MRproANP and MRproADM as dependent variables.
 Results 
 Patient Characteristics 
 A total of 105 patients (GOLD II, n = 29; GOLD III,
n = 42; GOLD IV, n = 34) were included in the study. De-
mographics and clinical characteristics of the study pop-
ulation are depicted in  table 1 . The mean age of the pa-
tient population was 66.1  8 8.7 years and 71% were men. 
Most patients were taking a long-acting anticholinergic 
agent (85%) and a combination of ICS/LABA 82 (84%).
Table 1.  Patient demographics and clinical parameters
GOLD II III IV p value
Patients 29 42 34
Male/female 21/8 32/10 22/12 0.55
Age, years 64.487.9 65.188.8 68.888.8 0.090
BMI 27.885.9 27.386.4 23.884.4 0.010*
Current or former smoker 29 42 34 0.99
SpO2 saturation 95.382.0 94.682.4 94.082.7 0.085
FEV1% 59.985.9 42.087.0 28.8810.7 <0.0001*
SGRQ total score 33.2820.8 37.6815.3 46.1816.0 0.013*
MMRC 2.380.77 2.680.86 3.280.84 <0.0001*
Age-adjusted Charlson score 4.582.5 4.482.9 4.782.5 0.94
Depression 3 (6.5) 4 (10) 7 (21) 0.18
MRproANP, pmol/l 67.2 (51–115) 95.4 (51–188) 115 (66–178) 0.10
MRproADM, pmol/l 0.575 (0.50–0.67) 0.670 (0.53–0.97) 0.700 (0.58–0.1.1) 0.033*
Total walk, min/day 64.1834.5 50.7823.2 42.6829.2 0.014*
Steps per day 5,15682,830 4,46382,151 3,30882,367 0.011*
Fast walk, min/day 4.288.1 2.985.4 0.4781.0 0.024*
Medication
Long AC 20 (69) 35 (83) 28 (82) 0.21
ICS/LABA 21 (72) 33 (83) 27 (79) 0.18
LTOT 0 0 20 (80) <0.0001*
-Blocker 7 (25) 15 (36) 17 (50) 0.58
ACE inhibitor 9 (32) 17 (40) 10 (29) 0.61
D ata are presented as mean 8 SD and median (IQR) for biomarkers proANP and proADM, or n (%). Overall group comparison 
across different GOLD stages was done using one-way ANOVA; post hoc group differences were tested by t test.  Long AC = Long-
acting anticholinergic; ICS/LABA = fixed combination of ICS/LABA; LTOT = oxygen therapy. * Statistical significance was set at 
p ≤ 0.05.
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 Activity Data 
 The overall mean wearing time of the accelerometer 
was 10.7  8 2.9 h/day. There was a statistical difference 
(p  ! 0.05) in minutes per day in total walking time, fast 
walking and steps per day between GOLD II, III and IV. 
 Bivariate Correlations 
 Significant correlations (p  ^  0.01) with both 
MRproANP and MRproADM are listed in  table  2 and 
include age, age-adjusted Charlson score, MMRC, total 
walk, fast walk, and steps per day. SGRQ total score 
showed a significant correlation with MRproADM (p = 
0.01) but not MRproANP (p = 0.046). FEV 1 (% predicted), 
SpO 2 , depression, BMI and smoking status showed no sig-
nificant correlation with either biomarker. There was a 
significant negative correlation between total walk and 
MRproANP with regression index (R 2 = 0.34; p  ! 0.001) 
and an estimated regression equation of: MRproANP = 
–1.53 – 7.25  ! total walk ( fig. 1 ). Likewise, there was a 
significant negative correlation between total walk and 
MRproADM with regression index (R 2 = 0.33; p  ! 0.001) 
and an estimated regression equation of: MRproADM = 
–0.006 – 7.08 ! total walk ( fig. 2 ). There was also a sig-
nificant negative correlation found between fast walk and 
MMRC (R = –0.70; p  ! 0.001).
 Multivariate Regression Analyses 
 We ran stepwise multivariate regression analyses with 
either MRproANP or MRproADM as dependent vari-
ables ( table 3 ). The first model included age, age-adjusted 
Charlson score, MMRC, SRGO total score and total
walk as covariates. The only independent predictors of 
MRproANP in this model were age and total walk (p = 
0.015 and p  ! 0.0001, respectively) and the only indepen-
dent predictor of MRproADM was total walk (p  ! 0.0001). 
In the second model we exchanged total walk with steps 
per day in the list of covariates and outcome remained 
similar. Here too, age and steps per day were the only in-
dependent predictors of MRproANP (p = 0.045 and p  ! 
0.0001, respectively) and steps per day only was indepen-
dently predictive of MRproADM (p  ! 0.0001). Finally,
we added fast walk as a covariate instead of either total 
walk or steps per day. In this model, none of the above-
mentioned covariates were independently predictive of 
MRproANP and the only independent predictor of 
MRproADM was MMRC (p = 0.006). Fast walk was
only independently predictive of MRproANP but not 
MRproADM once MMRC was excluded from the list of 
covariates (p = 0.023 and p = 0.057, respectively).
 Discussion 
 Our results indicate that daily walking activity is an 
independent predictor of MRproANP and MRproADM 
in stable COPD patients, two prognostic biomarkers 
markedly elevated upon exacerbation of COPD and pre-
dictive of increased mortality risk. The daily amount of 
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Table 2. S ignificant correlations with MRproADM and MRproANP
MRproADM (R) p value MRproANP (R) p value
Age, years 0.32 0.001* 0.39 <0.0001*
FEV1 (% predicted) –0.16 0.11 –0.12 0.24
SpO2 –0.22 0.025 –0.20 0.040
Age-adjusted Charlson score 0.35 <0.0001* 0.39 <0.0001*
Depression –0.012 0.90 0.003 0.977
Smoking 0.089 0.369 0.17 0.077
BMI 0.232 0.019 –0.04 0.70
MMRC dyspnea scale 0.54 <0.0001* 0.43 <0.0001*
SGRQ total score 0.33 0.01* 0.20 0.046
Total walk, min/day –0.57 <0.0001* –0.58 <0.0001*
Fast walk, min/day –0.33 <0.0001* –0.37 <0.0001*
Steps per day –0.49 <0.0001* –0.50 <0.0001*
B ivariate correlations of nonparametric variables using Pearson’s correlation coefficient R. SpO2 = Resting SpO2 saturation. * Sta-
tistical significance was set at p ≤ 0.01.
Table 3.  Multivariate regression analysis with total walk or steps per day as covariates
Dependent variable Model covariates Regression coefficient B (95% CI) p value
Model 1
MRproANP Constant
Age, years
Age-adjusted Charlson score 
MMRC dyspnea scale
SGRQ total score
Total walk, min/day
48.2 (–68.0; 164)
2.20 (0.43; 4.0)
–1.24 (–7.09; 4.6)
–4.7 (–27.9; 18.4)
0.41 (–0.53; 1.34)
–1.5 (–2.0; –0.93)
0.41
0.015*
0.67
0.69
0.39
<0.0001*
MRproADM Constant
Age, years
Age-adjusted Charlson score 
MMRC dyspnea scale
SGRQ total score
Total walk, min/day
0.55 (–0.11; 0.98)
0.003 (–0.004; 0.009)
0.006 (–0.016; 0.027)
0.03 (–0.05; 0.12)
0.003 (–0.002; 0.006)
–0.004 (–0.007; –0.002)
0.014
0.39
0.60
0.43
0.12
<0.0001*
Model 2
MRproANP Constant
Age, years
Age-adjusted Charlson score 
MMRC Dyspnea scale
SGRQ total score
Steps per day
14.3 (–108; 137)
1.9 (0.03; 3.8)
–0.45 (–6.7; 5.8)
5.7 (–18.3; 29.7)
0.37 (–0.62; 1.37)
–0.013 (–0.019; –0.006)
0.82
0.045*
0.89
0.64
0.46
<0.0001*
MRproADM Constant
Age, years
Age-adjusted Charlson score 
MMRC dyspnea scale
SGRQ total score
Steps per day
0.44 (–0.01; 0.89)
0.002 (–0.005; 0.009)
0.008 (–0.015; 0.031)
0.067 (–0.021; 0.15)
0.003 (–0.001; 0.006)
–0.0004 (–0.0006; –0.0001)
0.055
0.56
0.48
0.13
0.15
<0.0001*
M ultivariate regression analysis with MRproANP and MRproADM as dependent variables and either total walk (model 1) or steps 
per day (model 2) included in the lists of covariates. * Statistical significance was set at p ≤ 0.05.
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physical activity was inversely proportional to levels of 
circulating MRproADM across increasing GOLD stages, 
meaning that GOLD IV patients presented with lowest 
levels of daily walking activity and highest levels of 
 circulating MRproADM. This linear trend between ac-
tivity and biomarker expression was not observed for 
MRproANP. Although our data suggests a meaningful as-
sociation between physical activity and both biomarkers 
associated with cardiac distress in stable COPD patients, 
this association seems significantly more pronounced 
with MRproADM, a more novel biomarker known for its 
diagnostic capabilities in the presence of acute heart fail-
ure  [39] . MRproADM is considered a surrogate marker of 
overall cardiopulmonary distress including the develop-
ment of transient myocardial dysfunction due to its coun-
ter regulatory properties in response to bronchoconstric-
tion, pulmonary arterial hypertension, airway inflamma-
tion and/or infection during exacerbation of COPD  [12] .
 The development of underlying cardiovascular dis-
ease, in particular heart failure, is a common cause for 
mortality in COPD. The recent TORCH study was able to 
show that 30% of deaths in COPD patients were related 
to cardiovascular morbidity and 40% were due to COPD 
 [40] . Stolz et al.  [12] were able to demonstrate the impor-
tance of systemic biomarkers of cardiac distress in pa-
tients with COPD by suggesting that MRproANP and 
MRproADM, both well recognized in terms of clinical 
prognosis in cardiovascular disease and/or heart failure, 
also show prognostic significance in COPD in terms of 
hospitalization due to exacerbation and long-term sur-
vival  [11, 41] . Moreover, Watz et al.  [42] were able to dem-
onstrate higher values of systemic inflammation markers 
and concomitant cardiovascular comorbidities such as 
left ventricular dysfunction in physically inactive pa-
tients with COPD compared to those that showed moder-
ate activity levels.
 A recent study by Garcia-Rio et al.  [14] was able to 
show a linear dose-response relationship between accel-
erometer-derived physical activity levels and mortality or 
hospital admission due to severe acute exacerbations of 
COPD. The authors suggest that physical inactivity aug-
ments exacerbation of COPD, rather than vice versa, 
leading to more frequent hospital admission due to exac-
erbation compared with patients who showed moderate 
to high levels of physical activity  [14] . In addition, it has 
been shown that patients who were markedly inactive fol-
lowing hospital discharge after exacerbation of COPD 
were more likely to be readmitted if activity levels re-
mained low  [43] . Similar results have been reported using 
self-reported physical activity levels and health status 
questionnaires  [13, 25] . Our data adds to this existing 
pool of evidence by linking physical activity to two novel 
cardiac biomarkers known for their clinical significance 
in predicting outcome in COPD patients. Therefore, we 
hypothesize that the use of daily activity monitoring 
might prove useful in order to simplify risk stratification 
of COPD patients in daily living and thus facilitate early 
recognition of patients at risk.
 Previous investigators have shown only weak correla-
tions with lung parameters, particularly the degree of air-
way obstruction and physical activity levels  [14, 22, 44] . 
Nevertheless, walking intensity is attenuated by disease 
severity and markedly reduced in patients with higher 
GOLD stages  [18–22, 45, 46] . In our study population the 
level of exertional dyspnea was found to be a significant 
confounder in regards to the predictive strength of walk-
ing intensity but not walking volume on circulating levels 
of prognostic biomarkers. Seemingly, exertional dyspnea 
arises from airflow limitation due to vasoconstriction of 
the pulmonary vasculature, thus limiting movement in-
tensity. However, caution should be taken when solely us-
ing absolute activity volume (min/day) irrespective of in-
tensity, as patients with COPD tend to show intermittent 
activity spurts instead of continuous movement allowing 
for total activity to possibly be overestimated  [18–22] .
 In conclusion, we could show an independent and sig-
nificant association between walking activity assessed by 
accelerometry and two prognostic biomarkers of cardiac 
distress in patients with COPD. Employing activity mon-
itors in stable COPD patients enables continuous patient 
monitoring in a real-life setting and might simplify risk 
stratification by enabling early recognition of patients at 
risk for exacerbation of COPD. Subsequent future studies 
are needed, however, to evaluate whether continuous ac-
tivity monitoring can ascertain exacerbation of COPD in 
patients at risk and if changes in daily physical activity 
can be directly associated to changes in circulating bio-
markers of cardiac distress.
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